Salarius Pharmaceuticals, Inc. — 2023 Form 10-K
Entity note: The supplied filing is for Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), not Decoy Therapeutics Inc. It reports the fiscal year ended December 31, 2023, rather than a standalone 2023 fourth quarter.
Business context
Salarius is a clinical-stage biopharmaceutical company developing cancer treatments. Its main programs are seclidemstat (SP-2577), an LSD1 inhibitor, and SP-3164, a targeted protein degrader. The company has no approved products and has never generated product-sale revenue. It substantially reduced its workforce and operating costs while evaluating strategic alternatives, including a sale, merger, licensing, or other transaction.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Product-sale revenue | None | None |
| Research and development expense | $7.17 million | $15.84 million |
| General and administrative expense | $5.72 million | $7.14 million |
| Net loss | $12.54 million | $31.61 million |
| Net loss per share | $3.84 | $14.88 |
| Net cash used in operating activities | $12.85 million | $17.60 million |
| Cash and cash equivalents at year-end | $5.90 million | $12.11 million |
| Working capital at year-end | $5.2 million | Not stated in the supplied text |
| Total liabilities at year-end | $1.30 million | $4.27 million |
Revenue and gross margin are not meaningful measures for this pre-commercial company; the filing reports no product sales. The 2023 net loss improved by $19.07 million year over year, primarily reflecting lower operating expenses and the absence of the $8.87 million goodwill impairment and $1.99 million acquired in-process R&D charge recorded in 2022. R&D costs fell $8.66 million, partly due to spending cuts and lower SP-2577 spending; G&A fell $1.42 million. The company received $6.92 million net from equity issuance in 2023 and paid $0.28 million on a note payable. A short-term insurance-premium note had a $0.29 million balance at year-end.
Material changes, outlook and risks
- Management said cash under reduced operating conditions was expected to support operations into the first half of 2025. However, the company and its auditor disclosed substantial doubt about its ability to continue as a going concern; the filing also says additional capital or a strategic partner is needed and that failure to secure either could lead to a wind-down, liquidation, or bankruptcy process.
- In 2023, the company cut more than half of its positions and curtailed sponsored clinical work. In February 2024, it announced further cost reductions; CEO David Arthur moved from full-time employment to a part-time consulting role while remaining CEO. The company reported two full-time employees as of March 8, 2024.
- SP-3164’s FDA-cleared IND was not enough to start a trial: a Phase 1 trial remained on hold pending funding or a strategic transaction. The MD Anderson SP-2577 hematologic-cancer trial was active and recruiting in January 2024. The company reported a 60% objective response rate and 60% disease-control rate among first-relapse Ewing sarcoma patients treated with seclidemstat plus chemotherapy; the supplied filing text does not clearly state the patient count underlying these rates.
- Nasdaq granted an additional bid-price compliance period through September 3, 2024. The company said it would seek a reverse split if needed; a March 2024 preliminary proxy proposed a 1-for-4 to 1-for-8 split range.
- Outstanding warrants totaled approximately 10.84 million at December 31, 2023, compared with 597,512 a year earlier. Certain warrants carry rights in a fundamental transaction that could reduce proceeds available to common stockholders or complicate a transaction or financing.
- The CPRIT grant expired during 2023. No material legal proceedings were reported. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is Salarius Pharmaceuticals, not Decoy Therapeutics.
- Review current cash, spending, and financing or strategic-transaction progress against the stated runway and going-concern warning.
- Check the status and terms of any proposed transaction, including warrant-related payments or participation rights that could affect common-stockholder proceeds.
- Verify the latest Nasdaq bid-price compliance status and whether a reverse split was approved or implemented.
- Examine the clinical-trial data supporting the reported Ewing sarcoma response rates, including patient numbers, duration of response, safety, and FDA-agreed development requirements.
- Assess potential dilution from the large warrant balance and any subsequent equity financing.